Neutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine tumors.

Although the prognostic role of neutrophil-lymphocyte ratio (NLR) has been confirmed in a variety of tumors, the prognostic role of NLR in pancreatic neuroendocrine tumors (PNETs) has not been examined. The present study was performed to assess the role of NLR as a prognostic factor in patients with PNETs. Clinical data were retrospectively retrieved from a single institution. The best cut-off value for baseline NLR levels was determined by the receiver operating characteristic (ROC) curve and area under the ROC curve. The primary event was overall survival and event times were assessed by the Kaplan-Meier method. Potential factors associated with the elevation of NLR in PNETs were examined. A total of 165 consecutive patients with pathologically confirmed PNETs were included in this study. The cutoff value of NLR was 2.4 by ROC curve (area under ROC curve, 0.70). NLR >2.4 was found to be a poor prognostic factor in the univariate and multivariate analyses. Patients with a NLR value >2.4 had a higher proportion of tumor size at >3 cm (P=0.001), TNM stage III or IV (P=0.019), and G2/G3 (P=0.003). We concluded that NLR is an independent predictor of overall survival for patients with PNETs. Aberrant elevation of NLR identifies high-risk patients with aggressive characteristics.

[1]  Zuqiang Liu,et al.  A comprehensive comparison of clinicopathologic and imaging features of incidental/symptomatic non-functioning pancreatic neuroendocrine tumors: A retrospective study of a single center. , 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[2]  Sheng-guang Yuan,et al.  Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis. , 2015, World journal of gastroenterology.

[3]  T. Mukhtar,et al.  Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group , 2015, Annals of Surgical Oncology.

[4]  Zuqiang Liu,et al.  Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy , 2014, Annals of Surgical Oncology.

[5]  D. Bentrem,et al.  Comparison of tumor markers for predicting outcomes after resection of nonfunctioning pancreatic neuroendocrine tumors. , 2014, Surgery.

[6]  S. Boorjian,et al.  Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy. , 2014, Urologic oncology.

[7]  D. Santini,et al.  WHO 2010 classification of pancreatic endocrine tumors. is the new always better than the old? , 2014, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[8]  C. Landry,et al.  Biochemical prognostic indicators for pancreatic neuroendocrine tumors and small bowel neuroendocrine tumors. , 2014, Gland surgery.

[9]  J. Ahmad,et al.  Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review. , 2014, Hepatobiliary & pancreatic diseases international : HBPD INT.

[10]  Dan Huang,et al.  (18)F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors. , 2014, International journal of oncology.

[11]  T. O'Dorisio,et al.  Pancreastatin Predicts Survival in Neuroendocrine Tumors , 2014, Annals of Surgical Oncology.

[12]  D. Morris,et al.  A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. , 2014, Surgical oncology.

[13]  W. Willinek,et al.  Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  S. Clarke,et al.  The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. , 2013, Critical reviews in oncology/hematology.

[15]  P. Kornprat,et al.  Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer , 2013, British Journal of Cancer.

[16]  N. Malats,et al.  Risk of Pancreatic Cancer in Breast Cancer Families from the Breast Cancer Family Registry , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[17]  J. Scoazec,et al.  Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours? , 2012, European journal of cancer.

[18]  Fenghua Wang,et al.  Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer , 2012, Medical Oncology.

[19]  Feng Yang,et al.  Preoperative diagnosis of nonfunctioning pancreatic neuroendocrine tumors , 2011, Medical oncology.

[20]  B. Wiedenmann,et al.  From Targets to Treatments: A Review of Molecular Targets in Pancreatic Neuroendocrine Tumors , 2011, Neuroendocrinology.

[21]  A. Haynes,et al.  Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. , 2011, Archives of surgery.

[22]  R. Hall,et al.  Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. , 2010, American journal of surgery.

[23]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  K. Conlon,et al.  Pancreatic neuroendocrine tumours. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[25]  B. Eriksson,et al.  Endocrine tumours of the pancreas. , 2005, Best practice & research. Clinical gastroenterology.

[26]  D. Klimstra,et al.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  E. Seregni,et al.  Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.